Best ESG rating tier of negligible-risk with a top 1% global ranking score Industry and Regional ESG Top-Rated Company for five consecutive years Leader in Green CRDMO to drive innovation for a healthier futureSHANGHAI, July 16, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has elevated its Morningstar Sustainalytics ESG rating score to the highest negligible-risk tier, demonstrating its leadership ...

Core Viewpoint - WuXi Biologics demonstrates a strong commitment to sustainability through its 2024 Sustainability Report, highlighting significant advancements in sustainable development and corporate governance [1][3][15] Group 1: Sustainability Commitment - The company has successfully executed its "Follow and Win the Molecule" strategies while achieving notable sustainability milestones in 2024 [2] - WuXi Biologics has achieved a 30% intensity reduction in GHG emissions and a 28% reduction in water consumption compared to baseline years [7] - The Green CRDMO solution offers up to an 80% reduction in product carbon footprint, recognized by the United Nations Global Compact [9] Group 2: Governance and Stakeholder Engagement - The company has established strong corporate governance mechanisms aligned with the United Nations Sustainable Development Goals (UN SDGs) [3][4] - WuXi Biologics actively engages with stakeholders and participates in the Pharmaceutical Supply Chain Initiative (PSCI) to uphold principles in ethics, human rights, and environmental management [4] Group 3: Community and Employee Empowerment - The company supports career development for women in STEM, with 54% of STEM positions held by female employees, surpassing industry averages [5] - In 2024, nearly 10,000 employee volunteer hours were logged in local communities, emphasizing the company's commitment to social responsibility [6] Group 4: Recognition and Future Outlook - WuXi Biologics has received multiple accolades, including an MSCI AAA Rating and inclusion in the Dow Jones Sustainability Indices, reflecting its leadership in ESG [11] - Looking ahead, the company plans to continue prioritizing sustainability as a cornerstone of its innovation and operations, contributing to the UN Sustainable Development Goals [12]

Core Viewpoint - WuXi Biologics has been recognized by CDP for its leadership in climate change disclosure and performance, achieving an "A-" score for the second consecutive year, highlighting its commitment to sustainability and environmental stewardship [1][2][4]. Company Achievements - WuXi Biologics has adopted an integrated strategy to address climate change, aiming for net-zero emissions by 2050 and achieving a 30% reduction in GHG emission intensity from 2020 levels in 2024 [3]. - The company has received multiple accolades for its sustainability efforts, including an MSCI AAA Rating, EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices for two consecutive years [4]. Environmental Initiatives - WuXi Biologics is committed to the Science Based Target initiative (SBTi) and actively pursues energy-saving initiatives, including process optimization and infrastructure upgrades [3]. - The company has achieved a 100% renewable electricity supply at its Ireland site and is deploying rooftop photovoltaic power projects [3]. Industry Context - CDP serves as a global standard for corporate environmental reporting, with nearly 25,000 companies reporting their environmental data in 2024, representing two-thirds of the global market value [2]. - The recognition from CDP is significant as it influences investment and procurement decisions towards a sustainable economy [2].